Click to go to DrugInjuryLaw Home

Legal information and news about prescription drug side effects
NuvaRing Case Evaluation Ortho Evra Case Evaluation Fosamax Case Evaluation Avandia Case EvaluationKetek Case Evaluation Zelnorm Case Evaluation Meridia Case Evaluation Zocor Case Evaluation
Vytorin Case EvaluationZetia Case Evaluation Yasmin Case Evaluation Ocella Case EvaluationYAZ Case Evaluation Levaquin Case Evaluation Byetta Case Evaluation Gianvi Case Evaluation

Free Case Evaluation

Ketek Information

What is Ketek?

KetekŪ is a prescription antibiotic drug made by Aventis Pharmaceuticals and known generically as telithromycin. Ketek is in a class of drugs called ketolide antibiotics, and is used to treat bacterial infections in the lungs and sinuses. Ketek has been associated with adverse side effects such as liver damage, liver disease, liver failure, and hepatitis.

All content by attorney Tom Lamb

Ketek Label Will Get Black Box Warning and Medication Guide for Patients

On February 12, 2007 the FDA issued a news bulletin to inform the public that Sanofi-Aventis SA's antibiotic Ketek (telithromycin) is to be prescribed only for community-acquired pneumonia, and that Ketek should no longer be prescribed for two lesser medical conditions, acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

FDA Advisory Panel Suggests "Black Box" Warning For Ketek and More Restricted Use
Sanofi-Aventis Antibiotic Ketek: Serious Side Effects Outweigh Benefits For Bronchitis and Sinusitis. While this FDA advisory panel did not recommend a Ketek recall, according to a December 13, 2006 report about Ketek by CBS News, there is a new Congressional probe under way to determine whether Ketek should remain on the market.

New Warning for Ketek in Canada Concerns Possible Serious Liver Problems
September 2006 "Dear Doctor" letter warns about hepatotoxicity risks including: hepatitis, liver disease, and liver failure. Acute liver failure . . . leading to liver transplant or death have been observed during or immediately after the completion of Ketek treatment.

FDA Drug Safety Office Wants Black Box Warning For Ketek Liver Problems
In mid-May 2006 the FDA's drug safety office recommended that a black box warning be added to the Ketek label, stating that "severe, life-threatening, and in some cases fatal" liver toxicity has been reported in patients taking Ketek. The recommendation came after FDA safety reviewers found that the antibiotic Ketek has been linked to 12 cases of liver failure, including four deaths, in the U.S.

Reports of Liver Problems Associated With Antibiotic Ketek Prompt Warnings
On January 20, 2006 the Annals of Internal Medicine made available online an "early" release version of a report that described three cases of liver problems associated with the antibiotic Ketek (telithromycin). The three cases described in the report involved patients at Carolinas Medical Center, in Charlotte, North Carolina, who developed serious liver problems after taking Ketek.

What is Ketek and Why is the FDA Warning About Liver Problems
The FDA issued a warning about Ketek following an article in the Annals of Internal Medicine that described three cases of severe liver toxicity, including one death, in patients using Ketek.

Ketek Class Actions
We believe an individual lawsuit is a better way to handle an adverse drug reaction or other injury or death caused by Ketek.

Ketek and Legal Compensation
How to get legal compensation for an injury or death resulting from an adverse reaction to Ketek.

Ketek Case Evaluation
The information you provide to us for this Free Case Evaluation will be treated as strictly confidential.  You will get a reply from us no later than the next business day.  Submitting a case evaluation does not obligate you to hire our law firm for your lawsuit.  We handle all cases on a contingency fee basis, which means that you will make no payment for our legal services until after we have succeeded in getting legal compensation for you.

Drug Injury Watch: Ketek News Commentary

  • US FDA advises that you should not stop taking any prescription medication before talking to your doctor.
  • Reports of serious drug side effects should be made to the US FDA MedWatch program.
  • The prescription drug names are registered trademarks of the respective drug companies.
  • is not affiliated with any of the drug companies, nor US FDA.
Law Offices of Thomas J. Lamb, P.A.
Lumina Station Suite 225
1908 Eastwood Road
Wilmington, NC 28403
Tel: (910) 256-2971   Fax: (910) 256-2972
Toll Free: (800) 426-9535